- Home
- BRains API
Brains API
The foundation of Brains' business and the engine driving all other segments. Built on world-class cannabinoid product development, advanced manufacturing capabilities, and deep clinical development expertise, this division serves pharmaceutical, nutraceutical, and animal health markets worldwide with strong contracted revenue and exclusive partnerships with industry leaders.
Market Leadership That Competitors Can't Replicate
Traditional pharmaceutical companies recognize cannabinoids as medicine's next frontier, but lack the specialized capabilities to compete at pharmaceutical-grade scale. This creates extraordinary opportunity for Brains Bio as the established leader with proven manufacturing excellence, positioning us to capture disproportionate value as global demand accelerates. Along with exclusive partnerships with global multinationals, we've transformed first-mover advantage into sustainable competitive moats.
Projected Value Distribution
Manufacturing Excellence
The global standard for quality, purity, and regulatory compliance.
Brains develops and manufactures cannabinoid APIs, nutraceutical ingredients, drug intermediates, and finished dosage forms from our 25,000 sq ft UK facility that represents a manufacturing capability fewer than five companies globally can replicate. EU-GMP certified for human and veterinary medicines with UK Home Office Schedule 1 licensing for controlled substances, our nine specialized production lines deliver 12.6 tons annually with zero quality failures across 500+ commercial batches, achieving pharmaceutical-grade standards that exceed industry capabilities: <0.15% impurity profiles, 36-month stability, complete ICH-Q7 compliance, and 0.000006% THC detection (the industry's lowest threshold).
This flexible, scalable capacity is reinforced by a global network of GMP-certified CDMO partners, ensuring regulatory compliance in any jurisdiction while enabling premium pricing and exclusive partnerships with pharmaceutical leaders who demand consistency and reliability for clinical trials and commercial applications, translating this infrastructure advantage directly into revenue security and partnership exclusivity that compounds over time.
API Portfolio
Five pharmaceutical-grade cannabinoids driving multiple revenue streams. CBD leads with 30+ clinical trials supported and comprehensive global regulatory packages. D9-THC and D8-THC leverage our Schedule 1 license for medical applications requiring controlled substance capabilities. CBN and CBG represent early-mover advantages in emerging therapeutics with premium pricing reflecting limited qualified competition.
• EU GMP CBD API
• Delta 9-THC
• Delta 8-THC
• CBN
• CBG
Strategic Partnerships with Pharmaceutical Leaders who Demand Excellence.
Validated by leading pharmaceutical and nutraceutical companies worldwide. Our customer base includes multinational pharmaceutical companies, established nutraceutical manufacturers, and innovative biotech firms developing next-generation cannabinoid therapies. These partnerships span exclusive supply agreements, formulation collaborations, and clinical development programs, validating our position as the trusted API supplier for companies requiring pharmaceutical-grade quality and regulatory compliance.
End-to-End Solutions
From API to finished dosage forms, Brains enables complete pharmaceutical solutions. Beyond bulk supply, we deliver IP-protected formulations and novel delivery technologies that improve absorption and therapeutic performance. Our end-to-end capabilities span pharmaceutical-grade API production through custom formulation development to finished product manufacturing, supported by comprehensive regulatory expertise and global distribution networks.
The blueprint standard for the industry
Full set of independent certifications
National Sanitation Foundation (NSF)
Non-genetically modified (Non-GMO) organism
Halal / Kosher/ Vegan
US drug master file (DMF) filed with the FDA and referenced
EU Active Substance Master File (ASMF) maintained
Drug Substance (DS) section investigational medicinal product dossier (IMPD)
Drug Product (DP) section IMPD available for different dosage forms via commercial partner
FDA IND opened for PK Study
MHRA CT approval for PK Study
TGA approval 2x in human Proof of Concept studies
ANVISA Phase III Clinical Trial
>30 Clinical Trials and Studies
A Scalable Foundation for Exponential Growth
Brains API division delivers significant contracted cash flow through proven pharmaceutical partnerships while positioning for exponential growth as cannabinoid therapeutics achieve mainstream adoption. Multiple catalysts including U.S. market entry, and customer base expansion create step-change valuation opportunities in the rapidly expanding $50+ billion pharmaceutical API market.
